Human KIR2DL4/CD158d Monoclonal Antibody induces IFN‑ gamma secretion in the NK-92 human natural killer lymphoma cell line in a dose-dependent manner, as measured using the Quantikine Human IFN‑ gamma ELISA Kit ...read more
killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4
killer Ig receptor
MHC class I NK cell receptor KIR103AS
natural killer cell inhibitory receptor
NK cell receptor
KIR2DL4 (also known as 2DL4, p49, CD158d, KIR103) is a type I transmembrane protein of the killer cell Ig-like receptor (KIR) family expressed on NK and subsets of gamma δT and memory/effector alpha beta T cells. KIR2DL4 is a unique KIR (1-3); alleles are not clonally restricted but are expressed codominantly (4) in all activated NK cells and constitutively on CD56hi NK cells. KIR members with two Ig-like domains (2D) usually express domains D1 and D2, but KIR2DL4 expresses D0 and D2. Other long-tailed (L) KIR have two cytoplasmic inhibitory signaling domains (ITIM), but KIR2DL4 has one ITIM and also exhibits characteristics of activating KIR (2). An arginine within the transmembrane sequence of KIR2DL4 interacts with the signaling molecule Fc epsilon RI-gamma, while in activating KIR, a transmembrane lysine interacts with DAP12 (1, 5). The KIR2DL4 gene is highly polymorphic. Seven splice variants missing one or more exons have been identified, but it is not clear whether these are expressed. Several of the nine alleles identified encode a frameshift creating a prematurely truncated protein. It is estimated that up to 25% of humans do not express KIR2DL4 capable of reaching the cell surface (1, 7, 10). Human KIR2DL4 is 65-83% amino acid identical to other primates. KIR receptors have no structural orthologs in non-primates, although mouse Ly49 proteins are functional orthologs. Cross-linking of KIR2DL4 induces NK cells to produce IFN-gamma (6, 7); stimulation with IL-2 upregulates cell surface expression on CD56dim cells and allows cytotoxicity (7). Although a role in immune privilege of the fetus has been suggested due to reported recognition of fetal trophoblast HLA-G by KIR2DL4 in the maternal decidua (11), subsequent data have not supported this recognition (1, 9).
Lanier, L.L. (2005) Annu. Rev. Immunol. 23:225.
Faure, M. and E.O. Long (2002) J. Immunol. 168:6208.
Selvakumar, A. et al. (1996) Tissue Antigens 48:285.
Chan, H-W. et al. (2003) J. Exp. Med. 197:245.
Kikuchi-Maki, A. et al. (2005) J. Immunol. 174:3859.
Rajagopalan, S. et al. (2001) J. Immunol. 167:1877.
Kikuchi-Maki, A. et al. (2003) J. Immunol. 171:3415.
Gedil, M.A. et al. (2005) Tissue Antigens 65:402.
Witt, C.S. et al. (2002) Eur. J. Immunol. 32:18.
Goodridge, J.P. et al. (2003) J. Immunol. 171:1768.
Ponte, M. et al. (1999) Proc. Natl. Acad. Sci. USA 96:5674.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our KIR2DL4/CD158d Antibody (181703) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.